Latest News

Meet clinical fellow, Joshua Skydel, MD, who aims to develop methods for using real-world data to evaluate the safety and effectiveness of disease-modifying antirheumatic drugs

Public companies, which accounted for about half of AI-enabled devices on the market, had a higher rate of recalls and a lower rate of clinical evidence, according to a JAMA study, co-authored by Yale's Dr. Joseph Ross.

The Department of Internal Medicine is pleased to welcome the following new staff, clinical fellows, postdoctoral fellows, postdoctoral associates, and postgraduate associates who recently joined the department.

Yale School of Medicine's Reshma Ramachandran, MD, MPP, MHS, discusses how expedited drug approvals by the F.D.A., with less evidence, can shift uncertainty onto doctors and patients.

YSPH Associate Professor Jason Schwartz says pediatricians and other frontline health care providers will play a key role in helping rebuild trust in vaccines, which has eroded in recent years.

Rare disease experts discussed a new regulatory pathway proposed for the FDA at Bio2025, an international convention considered the largest and most comprehensive event for biotechnology. YSM & YSPH Professor Joseph Ross said the pathway is likely not needed, but it may have some value.

Yale School of Medicine's Reshma Ramachandran, MD, MPP, MHS, assistant professor of medicine (general medicine), won the 2025 Bernard Lown Award for Social Responsibility.

Reshma Ramachandran, MD, assistant professor of medicine (general medicine) at Yale School of Medicine, discusses patients' use of compounded GLP-1s over expensive branded drugs.